Author Bio
Rachel primarily covers healthcare stocks for the Fool. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market.
Over the past year, tremendous strides have been made in the coronavirus vaccine race. At the same time, investors have rushed in droves to seize upon the upside potential of coronavirus vaccine stocks. Many of these companies have seen shares double, triple, or even quadruple.
Don t get me wrong quite a number of these high-flying coronavirus vaccine stocks were fundamentally great buys before the pandemic, and have only proved to be increasingly compelling investments in the aftermath of the market crash. But if you re not particularly enthused about the coronavirus vaccine stock craze, or you simply want to explore other recession-resilient buys, you ve come to the right place.
Accolade to buy virtual care startup for $450 million
Accolade to buy virtual care startup for $450 million
Modern Healthcare Illustration / Getty Images
Accolade, an employee benefits company that went public last year, on Friday said it plans to buy direct-to-consumer virtual primary care startup PlushCare for up to $450 million.
Accolade, which sells healthcare navigation and engagement tools to employers, will pay $40 million in cash and $340 million in Accolade common stock to acquire privately held PlushCare, according to the terms of the agreement. The company may pay up to an additional $70 million based on revenue milestones following the acquisition s closing.
After the acquisition closes, Seattle-based Accolade will begin offering virtual primary care and mental health services to members through San Francisco-based PlushCare s network of clinicians. The company s primary-care and internist physicians consult with patients via text messaging and video telehealth and c
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Apr 14, 2021 at 6:45AM
When a stock goes up or down a lot in a short amount of time, it s easy to think something has changed. That volatility can often be a distraction. The most successful investors are able to focus on whether the company has a clear path to making money and how well that journey is going.
After a huge gain in 2020, shares of
Teladoc Health (NYSE:TDOC) are down almost 40% in two months. However, management continues to articulate plans to dominate the virtual healthcare industry and deliver numbers to prove it. As the decline scares people off, now could be a great time to buy the stock.
Caption Health Announces Steve Cashman as New President and CEO yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.